development of antibodies
![Inhibrx logo](/files/LOGO/1739614-INBX.png)
Company profile
Ticker
INBX
Exchange
Website
CEO
Mark Paul Lappe
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
SEC CIK
Corporate docs
IRS number
824257312
INBX stock data
Latest filings (excl ownership)
15-12G
Securities registration termination
10 Jun 24
S-8 POS
Registration of securities for employees (post-effective amendment)
30 May 24
S-8 POS
Registration of securities for employees (post-effective amendment)
30 May 24
S-8 POS
Registration of securities for employees (post-effective amendment)
30 May 24
S-8 POS
Registration of securities for employees (post-effective amendment)
30 May 24
POSASR
Automatic shelf registration (post-effective amendment)
30 May 24
8-K
Termination of a Material Definitive Agreement
30 May 24
25-NSE
Exchange delisting
30 May 24
8-K
Inhibrx Inc. Stockholders Approve Sale of INBRX-101 to Sanofi
24 May 24
DEFA14A
Additional proxy soliciting materials
20 May 24
Latest ownership filings
SC 13G/A
VIKING GLOBAL INVESTORS LP
3 Jun 24
4
OLE ANDREAS HALVORSEN
3 Jun 24
4
Inhibrx Biosciences, Inc.
31 May 24
4
Kristiina MD Vuori
30 May 24
4
KIMBERLY MANHARD
30 May 24
4
Mark Lappe
30 May 24
4
Jon Faiz Kayyem
30 May 24
4
DOUGLAS FORSYTH
30 May 24
4
Brendan P. Eckelman
30 May 24
4
Kelly Deck
30 May 24
Financial summary
Quarter (USD) | Mar 24 | Dec 23 | Sep 23 | Jun 23 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 23 | Dec 22 | Dec 21 | Dec 20 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 252.48 mm | 252.48 mm | 252.48 mm | 252.48 mm | 252.48 mm | 252.48 mm |
Cash burn (monthly) | 8.48 mm | (no burn) | 26.24 mm | 22.15 mm | 21.02 mm | 18.03 mm |
Cash used (since last report) | 32.79 mm | n/a | 101.45 mm | 85.65 mm | 81.26 mm | 69.73 mm |
Cash remaining | 219.69 mm | n/a | 151.04 mm | 166.83 mm | 171.22 mm | 182.75 mm |
Runway (months of cash) | 25.9 | n/a | 5.8 | 7.5 | 8.1 | 10.1 |
Institutional ownership, Q1 2024
13F holders | Current |
---|---|
Total holders | 125 |
Opened positions | 52 |
Closed positions | 20 |
Increased positions | 25 |
Reduced positions | 30 |
13F shares | Current |
---|---|
Total value | 1.31 tn |
Total shares | 38.11 mm |
Total puts | 91.30 k |
Total calls | 64.82 k |
Total put/call ratio | 1.4 |
Largest owners | Shares | Value |
---|---|---|
Viking Global Investors | 7.15 mm | $249.99 bn |
Perceptive Advisors | 4.26 mm | $148.79 bn |
BLK Blackrock | 2.75 mm | $96.20 bn |
Ra Capital Management | 2.63 mm | $91.94 bn |
STT State Street | 2.42 mm | $84.52 bn |
Vanguard | 1.86 mm | $65.08 bn |
TCG Crossover Management | 1.75 mm | $61.19 bn |
Sofinnova Investments | 1.30 mm | $45.54 bn |
Citadel Advisors | 1.20 mm | $42.10 bn |
Alpine Associates Management | 1.05 mm | $36.86 bn |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
30 May 24 | Douglas Forsyth | Common Stock | Sale back to company | Dispose D | Yes | No | 30 | 598,257 | 17.95 mm | 0 |
30 May 24 | Douglas Forsyth | Stock Option Common Stock | Sale back to company | Dispose D | No | No | 24.78 | 15,000 | 371.70 k | 0 |
30 May 24 | Douglas Forsyth | Stock Option Common Stock | Sale back to company | Dispose D | No | No | 12.57 | 15,000 | 188.55 k | 0 |
30 May 24 | Douglas Forsyth | Stock Option Common Stock | Sale back to company | Dispose D | No | No | 23.03 | 15,000 | 345.45 k | 0 |
30 May 24 | Douglas Forsyth | Stock Option Common Stock | Sale back to company | Dispose D | No | No | 10.52 | 17,259 | 181.56 k | 0 |
30 May 24 | Kelly Deck | Stock Option Common Stock | Sale back to company | Dispose D | No | No | 23.3 | 21,250 | 495.13 k | 0 |
30 May 24 | Kelly Deck | Stock Option Common Stock | Sale back to company | Dispose D | No | No | 33.63 | 14,583 | 490.43 k | 0 |
30 May 24 | Kelly Deck | Stock Option Common Stock | Sale back to company | Dispose D | No | No | 34.16 | 9,167 | 313.14 k | 0 |
30 May 24 | Jon Faiz Kayyem | Common Stock | Sale back to company | Dispose D | Yes | No | 30 | 25,000 | 750.00 k | 0 |
30 May 24 | Jon Faiz Kayyem | Common Stock | Sale back to company | Dispose D | Yes | No | 30 | 25,000 | 750.00 k | 0 |
Press releases
Inhibrx Inc. Stockholders Approve Sale of INBRX-101 to Sanofi
24 May 24
Inhibrx, Inc. Announces Updated When-Issued Trading Date for Anticipated Spin-Off
10 May 24
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates SWN, INBX, AVRO
10 May 24
INHIBRX INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Inhibrx, Inc. - INBX
9 May 24
Inhibrx, Inc. Announces Record Date and Expected Distribution Time for Anticipated Spin-Off and the Expected Merger Effective Time for Anticipated Merger
8 May 24